Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 2. Hazard Ratio estimates in subgroup analysis based on the stratification factors. Hazard ratios (HR) are estimated with a proportional hazards model stratified by prior exposure to PARP inhibitor (PARPi) (yes vs no) and prior immune checkpoint inhibitor (ICi) (yes vs no). Abbreviations: D, durvalumab; C, cediranib; O, olaparib; SOC, chemotherapy.
Authors: Jung-Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John, Chirag A. Shah, Koji Matsuo, Jean Siedel, David S. Miller, Elizabeth E. Hopp, Andrea O’Shea, John K. Chan, Leslie S. Bradford, Christopher B. Morse, Christa I. Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. Liu
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411285653